Polk H C, Calhoun J H, Lowrey L D, Blanchard S P, Brewer R J, Adams S T, Chedid L
Surgery. 1981 Aug;90(2):376-80.
Enhancement of nonspecific host defenses against bacterial challenge has been a long-standing goal often thwarted by variable efficacy, inconsistent bioassay, and paradoxic immunosuppression. Muramyl dipeptide provides enhanced survival after intravenous challenge with less than 8 x 10(3) Klebsiella, as well as improved local control of infection at sites of intramuscular bacterial injection, with and without a surgical foreign body. No depression of host response was seen over wide ranges of doses and intervals. Muramyl dipeptide provides a new order of efficacy and safety and warrants continued careful assessment.
增强机体对细菌攻击的非特异性宿主防御能力一直是一个长期目标，但常常因疗效不一、生物测定结果不一致以及矛盾的免疫抑制作用而受阻。静脉注射少于8×10³ 肺炎克雷伯菌后，胞壁酰二肽可提高生存率，在有或无外科异物的情况下，还可改善肌肉内细菌注射部位的局部感染控制。在很宽的剂量范围和给药间隔内均未观察到宿主反应受到抑制。胞壁酰二肽提供了新的疗效和安全性水平，值得继续进行仔细评估。
